Cardiology

The application to the FDA for icosapent ethyl seeks a new indication to reduce the risk of major adverse cardiovascular events.

MD Magazine sat down with Chirag Barbhaiya, MD, of NYU Langone Health, to discuss the updated guidelines for treating a patient with Afib.

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

A new cohort assessment shows white and African American men both have a lifetime hypertension risk of more than 80%.

Investigators observed a 22% and 20% increased risk of heart failure during the 2 most severe influenza seasons.

A short account of patients I’ve known and not loved over the years.

A 52-year-old female with a history of breast cancer is sent to the ED by her oncologist for a mild headache that's lasted 10 days. What does the EKG show?

The American College of Cardiology and the American Heart Association have updated treatment recommendations for the primary prevention of cardiovascular disease. Among the recommendations:  Stop recommending aspirin to prevent CVD.

No significant differences in cardiovascular outcomes among patients receiving different GLP-1 agonists including exenatide extended-release, exenatide immediate-release, liraglutide, albiglutide, and dulaglutide.

How the PIONEER-HF and PARADIGM-HF trials have focused on varied, but realistic heart failure patients.

A year-long outpatient care study showed that patients with type 2 diabetes and comorbid cardiovascular disease are 5 times as likely to visit a cardiologist.

It's been 4 years since the drug class reached the market. Are patients adhering to the therapy, and what more potential does it have?

The Apple Heart Study examined more than 400,000 patients over the course of a year, but some experts were less than thrilled with the outcomes.

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

The breakthrough device is indicated to improve 6-minute walk distance for certain patients with chronic heart failure.

What researchers from the low-risk TAVR trial anticipate they will find in their decade-long assessment.

With cardiovascular drug classes inhibitors owning discussion, how will recent or upcoming guideline updates address their use alongside lifestyle management?

The applications seek FDA approval for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes.

Study finds that cardiovascular disease accounts for almost 40% of deaths in young adults with end-stage renal disease.

Death, stroke and re-hospitalizations were reduced by 46 percent in low-risk patients with severe aortic stenosis who opted for a minimally invasive procedure over open heart surgery to repair the aortic valve.

Atrial fibrillation patients at risk for acute coronary syndrome, stroke and blood clots have better outcomes with an antithrombotic regimen of apixaban without aspirin, researchers report.

Progress in invasive measures for cardiovascular conditions has allowed clinicians the ability to venture into new ground.

What plans are held to progress the impressive findings of an envelope for cardiovascular device infection?

An extension of the study showed sacubitril/valsartan's benefit as an initial hospitalized heart failure therapy.

Observed data from a 96,000-plus participant survey found the popularized cigarette alternative is also associated with a greater risk of depression.